Leading radiosurgery systems maker
) recently revealed that it inked a collaboration and research
agreement with Erasmus Medical Center (MC), the largest university
medical center in the Netherlands. As per the agreement, the two
parties will collaborate on research in the field of radiation
oncology with the purpose of giving healthcare practitioners the
latest tools for patient care.
ACCURAY INC (ARAY): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis
To read this article on Zacks.com click here.
The two sides already have an extended history of collaboration.
Erasmus MC's clinical expertise with Accuray's CyberKnife System
enables it to appreciate the benefits derived by cancer patients
from radiosurgery. It looks forward to continued joint endeavor to
validate radiosurgery as a science and confirm the clinical
usefulness of the CyberKnife System.
Erasmus MC installed its first CyberKnife Robotic Radiosurgery
System in 2004, making it the fourth installation, in Europe,
India, Mid East and Africa, during that period. Till date, Erasmus
MC has provided therapy to over 1,000 patients with the CyberKnife
System besides carrying out significant clinical research. It has
also implemented innovative research techniques to study the
performance of the CyberKnife System.
During the last quarter, Accuray revealed two more collaboration
and research agreements with the University of Heidelberg and the
German Cancer Research Center (Deutsches Krebsforschungszentrum,
DKFZ), both in Heidelberg, Germany.
Accuray is a renowned radiation oncology company with a history of
rapid innovation and cutting-edge technologies. CyberKnife and the
TomoTherapy Systems comprise two of its flagship products.
CyberKnife is a full body radiosurgery device used to treat
cancerous tumors and TomoTherapy Systems are fully integrated and
advanced radiation therapy systems for all types of cancer
The company installed 22 new CyberKnife and TomoTherapy systems
during the most recent quarter, taking the aggregate global
installed base to 635 units. The company added $64.2 million of new
system orders in the quarter, leading to a total system backlog of
However, Accuray remains susceptible to reimbursement uncertainties
and faces stiff challenges from competitive product offerings of
Varian Medical Systems
). We currently have a Neutral recommendation on Accuray. The stock
currently retains a short-term Zacks #3 Rank (Hold).